Cargando…

63. Impact of Infectious Disease Fellow-Driven Antimicrobial Stewardship Interventions on Inpatient Fluoroquinolone Use

BACKGROUND: Fluoroquinolone (FQ) antibiotics are frequently used in hospitalized patients to treat a wide range of infections but are often misused and implicated in antibiotic-associated adverse events. The purpose of this study is to evaluate the impact of Infectious Disease fellow (IDF)-driven an...

Descripción completa

Detalles Bibliográficos
Autores principales: Nunez, Carlos M, Mattappallil, Arun, McCrink, Katie A, Rybak, Debbie, Taha, Basil, Chew, Debra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644436/
http://dx.doi.org/10.1093/ofid/ofab466.265
_version_ 1784610085149868032
author Nunez, Carlos M
Mattappallil, Arun
McCrink, Katie A
Rybak, Debbie
Taha, Basil
Chew, Debra
author_facet Nunez, Carlos M
Mattappallil, Arun
McCrink, Katie A
Rybak, Debbie
Taha, Basil
Chew, Debra
author_sort Nunez, Carlos M
collection PubMed
description BACKGROUND: Fluoroquinolone (FQ) antibiotics are frequently used in hospitalized patients to treat a wide range of infections but are often misused and implicated in antibiotic-associated adverse events. The purpose of this study is to evaluate the impact of Infectious Disease fellow (IDF)-driven antimicrobial stewardship program (ASP) interventions on inpatient FQ use. METHODS: This is a retrospective study of all admitted patients who received a FQ for greater than 48 hours from 01/01/2019 -12/31/2020 in an urban academic center. “Phase 1” (pre-intervention phase) covered 01/1/2019- 03/31/2019. “Phase 2” (intervention phase) covered 03/03/2020- 12/23/2020. In “Phase 2”, our ASP reviewed FQ use 2-3 days per week and an IDF provided feedback interventions that averaged 30-60 minutes of IDF time spent per day. We categorized FQ use as either: “appropriate”, “appropriate but not preferred”, or “inappropriate”, as determined by local clinical guidelines and ASP team opinion. We compared FQ use in both phases, indications for FQ use, and new Clostridioides difficile infections (CDI). RESULTS: A total of 386 patients are included (76 in “Phase 1”and 310 in “Phase 2”). Patient characteristics are similar (Table 1). Overall, 63 % of FQ use was empiric, and 50% FQ use was deemed “appropriate”, 28% “appropriate but not preferred”, and 22% “inappropriate”. In “Phase 2”, 126 interventions were conducted, with 86% of these accepted. Appropriate FQ use increased significantly in “Phase 2” vs. “Phase 1” (53.5% vs 35.5%, p = 0.008), with decrease in mean days of FQ use (4.38 days vs 5.87 days, p =.021). Table 2 shows “appropriate” FQ use by clinical indication. New CDIs occurred more in “Phase 1” vs. “Phase 2” (6.6% vs 0.6%, p=.001). [Image: see text] [Image: see text] CONCLUSION: An IDF-driven ASP intervention has a positive impact on appropriate inpatient use of FQs in our hospital. This highlights a promising ASP model which not only improves appropriate use of FQ, but also offers an opportunity for IDF mentorship and use of available resources to promote ASPs. DISCLOSURES: Katie A. McCrink, PharmD, ViiV Healthcare (Employee)
format Online
Article
Text
id pubmed-8644436
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86444362021-12-06 63. Impact of Infectious Disease Fellow-Driven Antimicrobial Stewardship Interventions on Inpatient Fluoroquinolone Use Nunez, Carlos M Mattappallil, Arun McCrink, Katie A Rybak, Debbie Taha, Basil Chew, Debra Open Forum Infect Dis Poster Abstracts BACKGROUND: Fluoroquinolone (FQ) antibiotics are frequently used in hospitalized patients to treat a wide range of infections but are often misused and implicated in antibiotic-associated adverse events. The purpose of this study is to evaluate the impact of Infectious Disease fellow (IDF)-driven antimicrobial stewardship program (ASP) interventions on inpatient FQ use. METHODS: This is a retrospective study of all admitted patients who received a FQ for greater than 48 hours from 01/01/2019 -12/31/2020 in an urban academic center. “Phase 1” (pre-intervention phase) covered 01/1/2019- 03/31/2019. “Phase 2” (intervention phase) covered 03/03/2020- 12/23/2020. In “Phase 2”, our ASP reviewed FQ use 2-3 days per week and an IDF provided feedback interventions that averaged 30-60 minutes of IDF time spent per day. We categorized FQ use as either: “appropriate”, “appropriate but not preferred”, or “inappropriate”, as determined by local clinical guidelines and ASP team opinion. We compared FQ use in both phases, indications for FQ use, and new Clostridioides difficile infections (CDI). RESULTS: A total of 386 patients are included (76 in “Phase 1”and 310 in “Phase 2”). Patient characteristics are similar (Table 1). Overall, 63 % of FQ use was empiric, and 50% FQ use was deemed “appropriate”, 28% “appropriate but not preferred”, and 22% “inappropriate”. In “Phase 2”, 126 interventions were conducted, with 86% of these accepted. Appropriate FQ use increased significantly in “Phase 2” vs. “Phase 1” (53.5% vs 35.5%, p = 0.008), with decrease in mean days of FQ use (4.38 days vs 5.87 days, p =.021). Table 2 shows “appropriate” FQ use by clinical indication. New CDIs occurred more in “Phase 1” vs. “Phase 2” (6.6% vs 0.6%, p=.001). [Image: see text] [Image: see text] CONCLUSION: An IDF-driven ASP intervention has a positive impact on appropriate inpatient use of FQs in our hospital. This highlights a promising ASP model which not only improves appropriate use of FQ, but also offers an opportunity for IDF mentorship and use of available resources to promote ASPs. DISCLOSURES: Katie A. McCrink, PharmD, ViiV Healthcare (Employee) Oxford University Press 2021-12-04 /pmc/articles/PMC8644436/ http://dx.doi.org/10.1093/ofid/ofab466.265 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Nunez, Carlos M
Mattappallil, Arun
McCrink, Katie A
Rybak, Debbie
Taha, Basil
Chew, Debra
63. Impact of Infectious Disease Fellow-Driven Antimicrobial Stewardship Interventions on Inpatient Fluoroquinolone Use
title 63. Impact of Infectious Disease Fellow-Driven Antimicrobial Stewardship Interventions on Inpatient Fluoroquinolone Use
title_full 63. Impact of Infectious Disease Fellow-Driven Antimicrobial Stewardship Interventions on Inpatient Fluoroquinolone Use
title_fullStr 63. Impact of Infectious Disease Fellow-Driven Antimicrobial Stewardship Interventions on Inpatient Fluoroquinolone Use
title_full_unstemmed 63. Impact of Infectious Disease Fellow-Driven Antimicrobial Stewardship Interventions on Inpatient Fluoroquinolone Use
title_short 63. Impact of Infectious Disease Fellow-Driven Antimicrobial Stewardship Interventions on Inpatient Fluoroquinolone Use
title_sort 63. impact of infectious disease fellow-driven antimicrobial stewardship interventions on inpatient fluoroquinolone use
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644436/
http://dx.doi.org/10.1093/ofid/ofab466.265
work_keys_str_mv AT nunezcarlosm 63impactofinfectiousdiseasefellowdrivenantimicrobialstewardshipinterventionsoninpatientfluoroquinoloneuse
AT mattappallilarun 63impactofinfectiousdiseasefellowdrivenantimicrobialstewardshipinterventionsoninpatientfluoroquinoloneuse
AT mccrinkkatiea 63impactofinfectiousdiseasefellowdrivenantimicrobialstewardshipinterventionsoninpatientfluoroquinoloneuse
AT rybakdebbie 63impactofinfectiousdiseasefellowdrivenantimicrobialstewardshipinterventionsoninpatientfluoroquinoloneuse
AT tahabasil 63impactofinfectiousdiseasefellowdrivenantimicrobialstewardshipinterventionsoninpatientfluoroquinoloneuse
AT chewdebra 63impactofinfectiousdiseasefellowdrivenantimicrobialstewardshipinterventionsoninpatientfluoroquinoloneuse